Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Bausch + Lomb Corporation is a global eye health company focused on the development, manufacturing, and commercialization of products that support vision care and ocular health. The company operates primarily within the ophthalmology and vision care industries, serving consumers, eye care professionals, hospitals, and surgical centers. Its core activities span vision correction, ocular pharmaceuticals, and ophthalmic surgical devices, positioning it as one of the few fully integrated eye health companies worldwide.
The company’s primary revenue drivers include contact lenses, lens care products, prescription ophthalmic pharmaceuticals, and surgical instruments used in cataract and refractive procedures. Bausch + Lomb Corporation traces its origins to 1853, when it was founded in Rochester, New York, and has evolved through decades of expansion, innovation, and ownership changes. Most recently, the company became an independent publicly traded entity in 2022 following its separation from its former parent, Bausch Health Companies Inc., allowing it to pursue a more focused strategy centered exclusively on eye health.
Business Operations
Bausch + Lomb Corporation operates through three principal business segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment includes contact lenses, lens care solutions, and eye vitamins, with well-established brands that serve both daily wear consumers and eye care professionals. The Pharmaceuticals segment develops and markets prescription and over-the-counter ophthalmic drugs addressing conditions such as glaucoma, eye infections, inflammation, and dry eye. The Surgical segment provides ophthalmic surgical equipment, instruments, and intraocular lenses used primarily in cataract and refractive surgeries.
The company generates revenue through a combination of direct sales to eye care professionals, distributors, hospitals, and retail channels across domestic and international markets. It controls a global manufacturing and R&D infrastructure supporting product development, regulatory compliance, and supply chain operations. Bausch + Lomb Corporation operates through numerous wholly owned subsidiaries and maintains commercial partnerships to distribute products in markets where direct presence is limited.
Strategic Position & Investments
Strategically, Bausch + Lomb Corporation is focused on strengthening its position as a pure-play eye health company by investing in innovation, expanding its product pipeline, and increasing penetration in faster-growing vision care and ophthalmic pharmaceutical markets. Growth initiatives emphasize new contact lens technologies, sustained-release drug delivery systems, and next-generation intraocular lenses designed to improve surgical outcomes.
The company continues to invest in research and development while selectively pursuing acquisitions and licensing agreements that complement its core competencies. Notable investments have centered on expanding its pharmaceutical portfolio and enhancing surgical technology capabilities. These initiatives are intended to support long-term organic growth while reinforcing the company’s competitive differentiation across multiple segments of the eye health value chain.
Geographic Footprint
Bausch + Lomb Corporation maintains a broad global footprint, with headquarters in North America and significant operations across Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Its products are sold in more than 100 countries, supported by regional manufacturing facilities, distribution centers, and commercial offices.
The company’s international presence plays a critical role in revenue diversification, with substantial contributions from markets outside the United States. Emerging markets represent an important area of strategic focus, as rising rates of vision impairment and expanding access to eye care services drive long-term demand for the company’s products and technologies.
Leadership & Governance
Bausch + Lomb Corporation is led by an experienced executive team with backgrounds spanning pharmaceuticals, medical devices, and global consumer health. The leadership emphasizes operational discipline, scientific innovation, and long-term value creation through a focused eye health strategy. Corporate governance practices are aligned with public company standards, with oversight provided by an independent board of directors.
Key executives include:
- Brent Saunders – Chairman of the Board
- Brent Saunders – Chief Executive Officer
- Fred Hassan – Lead Independent Director
- Sam Eldessouky – Chief Financial Officer
- Yehia Hashad – Chief Technology Officer
- Joe Gordon – President, Global Consumer
The leadership team’s strategic vision centers on reinforcing the company’s heritage in eye care while accelerating innovation and global market expansion following its transition to an independent public company.